Key market opportunities for BCMA-targeted therapies include rising multiple myeloma cases, next-gen therapy approvals, ...

In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week cycles). Patients had progression after ≥ 2 lines of prior therapy and no extramedullary disease. Minimal ...

ベルギー Janssen Pharmaceutical社は5月25日、BCMA（B-Cell Maturation Antigen）を標的とするCAR-T細胞シルタカブタゲン オートルユーセル（cilta-cel）について、再発でレナリドミド抵抗性の多発性骨髄腫を対象に欧州で承認申請したと発表した。 cilta-celは、免疫調節薬 ...

Exploring nationwide trends in multiple myeloma (MM), autologous stem cell transplants (ASCTs), chimeric antigen receptor T-cell (CAR-T) therapy and coronavirus disease 2019 (COVID-19) in ...

Chimeric antigen receptor T cell therapy reduces vaccine immunity, with many patients lacking seroprotection despite stable antibody levels.

Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, ...

In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...